BLU-285 Targets KIT/PDGFRA Conformation and Activating Loop Mutations [Targeted Therapy]

The small-molecule inhibitor BLU-285 inhibits clinically relevant KIT and PDGFRA mutations.

from Cancer via ola Kala on Inoreader http://ift.tt/2m7Vkcj
via IFTTT